Author

Drew Lazenby

University of MiamiORCID 0009-0004-7120-1237Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Organism:human· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

Abdessamad Youssfi AlaouiiD· 1 shared Alexa Marie BarrosoiD· 1 shared Alexandra Marie CarboneiD· 1 shared Alicia Bilbao MartineziD· 1 shared Austin Daniel NewsamiD· 1 shared Daniel BilbaoiD· 1 shared Dhanvantri ChahariD· 1 shared Francesco MauraiD· 1 shared

Activity by Year

2025-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Abdessamad Youssfi AlaouiORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologyCancer ResearchPeer-reviewedJul 31, 2025

NRF2 translation block by inhibition of cap-dependent initiation sensitizes lymphoma cells to ferroptosis and CAR-T immunotherapy

Paola Manara, Austin Daniel Newsam, Venu Venkatarame Gowda Saralamma…·Jonathan Harry Schatz

This study shows that inhibiting cap-dependent translation in lymphoma cells increases sensitivity to ferroptosis and CAR-T therapy by reducing NRF2 expression.

13 citations

humanbulk RNA-seq